Bavarian Biotech News March 2022 Bavaria Tradition meets Innovation DEAR READER/NEWS Page 2 BAVARIA INTERNATIONAL Page 9 SPOTLIGHT COVID-19 RECENT HEADLINES Page 3 - 4 Page 5 - 6 BIOM EVENTS EVENTS & CONTACT Page 10 Page 12 BIOENTREPRENEURS IN BAVARIA Page 7 - 8

Spotlight COVID-19 A spray against lung damage due to COVID-19 The start-up rnatics of the Technical University of Munich (TUM) has developed an RNA-based active substance against inflammatory lung damage resulting from severe COVID-19 courses. The German Federal Ministry of Education and Research (BMBF) is now supporting the further development of the drug with 7 million euros. The rnatics team is focusing on a substance that blocks a pro-inflammatory microRNA. Moreover, the approach is virus variant-independent. Severe inflammation and scarring of the lung tissue are possible consequences of SARS-CoV2 infections. s c i t a n r © They can limit lung function in the long term and are one of the causes of the "long covid" phenomenon. A team led by Stefan Engelhardt, Professor of Pharmacology and Toxicology at TUM, has now developed a new RNA agent that can prevent this inflammatory lung damage. To this end, the active ingredient inhibits a specific microRNA in macrophages of the lung, which promotes the inflammatory process and occurs in very high concentrations in the lungs of COVID-19 sufferers. In the mouse model, it has already been shown that the new active substance specifically blocks the microRNA molecule. As a result, there was significantly less inflammation and lung damage, and lung function clearly improved. The therapeutic is based on the active ingredient RCS-21, a novel ligand-coupled oligonucleotide inhibitor. The RNA drug would be the first in its drug class to be targeted to macrophages. Read more… Ethris continues research on mRNA therapeutics with fresh USD 26.3 million Planegg-based biotechnology company Ethris has raised USD 26.3 million in a Series B funding round led by Laureus Capital. Ethris plans to use the money to further develop its mRNA therapeutics and proprietary platform, and to expand the company's production capacity. Ethris has been researching mRNA as therapeutics for more than 10 years, using its proprietary and technology platforms to develop therapies for various respiratory diseases with high unmet medical needs. Proceeds from the current financing will now be used primarily to investigate the company's two lead programs in clinical trials: k c o t s r e t t u h S © ETH47 for influenza and SARS-CoV-2 The company's ETH47 therapy candidate contains the mRNA blueprint for the type III interferon IFN-λ, which can be administered as a nasal spray directly into the respiratory tract. It locally activates the innate immune system at the virus entry site and acts broadly against respiratory viruses. Protein replacement therapy for primary ciliary dyskinesia (PCD) ETH42 is a protein replacement therapy for primary ciliary dyskinesia (PCD). PCD is a rare congenital disease due to structural defects or absence of the cilia that line our airways. In Germany, about 4000 patients suffer from it. The lack of mobility of the cilia leads to an inability to adequately clear the airways, which can often lead to permanent lung damage. Read more… Bavarian Biotech News, March 2022 www.bio-m.org 3

Recent Headlines Roche Penzberg: Groundbreaking ceremony for 250 million euro building At Roche in Penzberg, the start signal has been given for the construction of the new diagnostics research building LEAP. The groundbreaking ceremony marks the official start of construction work. The building is intended to set new standards for the research and development of diagnostic tests. The six-story building called LEAP (Laboratory Excellence Accelerator Penzberg), in which Roche is investing up to EUR 250 million, is being built in the south of the site. It is scheduled for completion in 2024 and will be the new workplace for more than 800 employees currently housed on the site and in Munich. H b m G s c i t s o n g a D e h c o R © i "The investment in the new building is a clear commitment by the Roche Group to Germany as a research and development location," plant manager Dr. Ulrich Opitz makes clear. "It will be an important part of our global competence network in the development of diagnostic tests and will strengthen the attractiveness of Penzberg as a location for science and innovation.“ The Roche site in Penzberg, which currently employs 7,200 people, is a very important economic pilar for Penzberg and the entire region. Read more… BioNTech and Medigene co-develop T-cell receptor immunotherapies against cancer The Mainz-based company BioNTech SE and the biotechnology company Medigene AG in Martinsried intend to jointly develop T-cell receptor-based immunotherapies for the treatment of cancer as part of a global collaboration. Under the terms of the agreement, Medigene will receive an upfront payment of EUR 26 million and be eligible for milestone payments. T-cell therapy has emerged as a promising treatment for cancer patients. This immunotherapeutic approach attempts to overcome the existing tolerance to cancer cells and tumor- induced suppression of an immune response. k c o t s r e t t u h S © As part of the collaboration, Medigene will contribute its proprietary TCR platform to develop T cell receptors against various targets selected by BioNTech to address a variety of solid tumors. BioNTech will acquire Medigene’s next generation preclinical TCR program, which combines TCR-4 of Medigene’s MDG10XX program targeting PRAME with Medigene’s proprietary PD1-41BB switch receptor technology. BioNTech will also obtain the exclusive option to acquire additional existing TCRs in Medigene’s discovery pipeline and will receive licenses to the company’s PD1-41BB switch receptor and precision pairing library. This has the potential to augment TCR cell therapy efficacy and can be applied to all BioNTech cell therapy programs. Medigene will receive EUR 26 million upfront, as well as research funding for the period of the collaboration. BioNTech will be responsible for global development. Read more… Bavarian Biotech News, March 2022 www.bio-m.org 5

BioEntrepreneurs in Bavaria Start-ups looking for funding at the 11th BioM-BioAngels Pitch Day Six selected founding teams presented their business ideas to interested investors and business angels at the 11th BioAngels Pitch Day. At BioM's exclusive matchmaking event, the potential of the life science scene with innovative ideas in the fields of drug development, digital health and medical technology was once again demonstrated. y a b a x P © i At the 11th BioAngels Pitch Day, promising pre-seed teams and start- ups again had the opportunity to convince potential funders with an investment focus on life sciences and healthtech of their technology and business model - in just 10 minutes, with scientific data and a sound business strategy. The BioAngels pitch event was again very well received by the start-ups as well as the investors. Due to the intensive pitch training by BioM in advance, the teams were well prepared for the in- depth questions of the invited investors after the pitches. The business ideas were broad. With the goal of raising seed funding successfully, new solutions in medical technology and telemonitoring were presented in addition to the development of innovative drugs for the treatment of tumor diseases. As part of its virtual incubator inQlab, BioM helps with the BioAngels matchmaking event young bioentrepreneurs find the right contacts with potential investors in the biomedical field. The next BioAngels Pitch Day will take place in the fourth quarter of 2022. Read more… m4 Award winners on the path to success Three winners of the m4 Award pre-seed competition have been successful. The Munich-based start-ups INVITRIS and Smartbax have received funding as part of INCATE. They want to find solutions against antibiotic resistances that are increasing worldwide and threatening health. The Knowing01 team has been awarded the Women TechEU grant, which aims to support women-led start-ups in cutting-edge technology. • Against drug-resistant pathogens: funding for INVITRIS and Smartbax y a b a x P © i INVITRIS uses bacteriophages for the therapy of antibiotic-resistant infections and has developed a special technology with which it is possible for the first time to produce genetically optimized bacteriophages in vitro for the therapy of antibiotic-resistant infections. Smartbax is a spin-off of the Technical University of Munich and was founded in April 2021. The start-up is developing novel antibacterial compounds against multidrug-resistant bacteria and difficult-to-treat biofilms. • Women TechEU grant for Knowing01 Knowing01, a spin-off of the Institute of Computational Biology at Helmholtz Zentrum München, can also announce a success. Founded in early 2020, the start-up has developed software for processing Big Data to identify biomarkers and drug targets for personalized therapies. Read more… Bavarian Biotech News, March 2022 www.bio-m.org 7

Bavaria International CE4BIG – European cluster network focusing on personalized medicine After two challenging, but successful years, the CE4BIG project – Cluster Excellence for Business, Innovation and Growth in the health sector – is coming to an end of its funding period. The four European healthcare clusters Atlanpole Biotherapies (France), BioM (Germany), BioWin (Belgium), and Klaster Life Science Krakow (Poland) joined forces and carry on as the CE4BIG alliance in personalized medicine. The project aimed at building up cluster management excellence and optimizing cluster services for SMEs in the personalized medicine sector. Despite the fact that the CE4BIG project ran almost entirely throughout the COVID-19 pandemic – from February 2020 to February 2022 – it has nonetheless contributed to stimulating innovation, mainly through virtual exchanges and SME trainings. The four clusters were also awarded ESCA Cluster Excellence labels. Impact for SMEs and other Cluster Members A series of activities were organized for cluster members throughout the CE4BIG project: • Training courses for SMEs • Bioproduction networking week • Info sessions on European funding opportunities for SMEs • Life Science Open Space Forum • Session on “Green Transition in Life Sciences” The CE4BIG cluster alliance will continue its work in response to European challenges in the field of personalized medicine: http://ce4big.lifescience.pl/ > 1300 participants coached 25 companies pitched to find European partners > 30 B2B meetings Cooperation and business relations with China - BioM services and support As the world's second largest economy and with the rapid development in the healthcare sector in recent years, China offers countless opportunities for biotech and biopharma companies. According to the study "Biotechnology and Pharmaceutical Industry in the European Metropolitan Region Munich (EMM ) 2021”, 34% of the companies have already on-going activities in China, 51% are interested in the Chinese healthcare market. German-Chinese Working Group for the Promotion of the Health and Medical Industry With the establishment of this working group Chinese and German companies are to receive support in expanding their activities in the other country. BioM China Workshop: ChinaBio® Partnering Forum: In order to serve the unmet needs of our cluster companies, a China Workshop is going to be carried out on April 6 - 7, as an on-site event at BioM. BioM is able to provide Bavarian biotech companies with a Bavarian joint booth, discounted (virtual) tickets and support during the conference. For specific questions regarding activities of your company targeting China, please contact Mrs. Dr. Ruoyu Sun: sun@bio-m.org. Bavarian Biotech News, March 2022 www.bio-m.org 9